Is pre-trial quality assurance necessary? Experiences of the CONVERT Phase III randomized trial for good performance status patients with limited-stage small-cell lung cancer

British Journal of Radiology

Volumn 87, Issue 1037, 2014, Pages

  Groom, N ^a   Wilson, E ^b   Lyn, E ^c   Faivre Finn, C ^d  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c CANCERCARE MANITOBA   (Canada)

^d CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE;

ALGORITHM; ARTICLE; CANADA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PROTOCOL; CONTROLLED STUDY; DOSIMETRY; ESOPHAGUS; EUROPE; HEART; HISTOGRAM; HUMAN; LUNG; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; ORGANS AT RISK; PHOTON THERAPY; QUALITY CONTROL; QUESTIONNAIRE; RADIOTHERAPY PLANNING SYSTEM; RANDOMIZED CONTROLLED TRIAL; SMALL CELL LUNG CANCER; THROMBECTOMY DEVICE; TREATMENT PLANNING; TUMOR VOLUME; VERTEBRAL CANAL; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; FEMALE; HEALTH CARE QUALITY; LUNG NEOPLASMS; MALE; PATHOLOGY; PATIENT POSITIONING; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION INJURIES; SMALL CELL LUNG CARCINOMA; STANDARDS; SURVIVAL RATE;

ALGORITHMS; CANADA; EUROPE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PATIENT POSITIONING; PROSPECTIVE STUDIES; QUALITY ASSURANCE, HEALTH CARE; QUESTIONNAIRES; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE;

EID: 84907485875     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr.20130653     Document Type: Article

References (23)

1. Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993; 11: 336-4.
2. Johnson BE, Bridges JD, Sobczeck M, Gray J, Linnoila RI, Gazdar AF, et al. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J Clin Oncol 1996; 14: 806-13.
3. Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340: 265-71. doi: 10.1056/NEJM199901283400403
4. Bayman NA, Sheikh H, Kularatne B, Lorigan P, Blackhall F, Thatcher N, et al. Radiotherapy for small-cell lung cancer - where are we heading? Lung Cancer 2009; 63: 307-14. doi: 10.1016/j.lungcan.2008.06.013
5. CONVERT Trial Protocol (final version 3). [updated 10 June 2008]. Available from: http:\\www.converttrial.com
6. Perez C, Gardner P, Glasgow GP. Radiotherapy quality assurance in clinical trials. Int J Radiat Oncol Biol Phys 1984; 10(Suppl. 1): 119-25.
7. Fairchild A, Bar-Deroma R, Collette L. Development of clinical trial protocols involving advanced radiation therapy techniques: the European Organisation for Research and Treatment of Cancer Radiation Oncology Group approach. Eur J Cancer 2012; 48: 1048-54. doi: 10.1016/j. ejca.2012.02.008
8. Donaldson SS, Torrey M, Link M, Glicksman L, Gilula F, Laurie F, et al. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys 1998; 42: 125-35.
9. Gwynne S, Spezi E, Sebag-Montefiore D, Mukherjee S, Miles E, Conibear J, et al. Improving radiotherapy quality assurance in clinical trials: assessment of target volume delineation of the pre-accrual benchmark case. Br J Radiol 2013; 86: 20120398. doi: 10.1259/bjr.20120398
10. Senan S, De Ruysscher D, Giraud P, Mirimanoff R, Budach V; Radiotherapy Group of European Organization for Research and Treatment of Cancer. Literaturebased recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 2004; 71: 139-46. doi: 10.1016/j.radonc.2003.09.007
11. Landberg T, Chavandra J, Dobbs HJ, Hanks G, Johansson KA, Muller R, et al. Report 62: prescribing recording and reporting photon beam therapy (supplement to ICRU report 50). Bethesda, MD: ICRU Publications; 1999.
12. Landberg T, Chavandra J, Dobbs HJ, Hanks G, Johansson KA, Muller R, et al. Report 50: prescribing, recording and reporting photon beam therapy. Bethesda, MD: ICRU Publications; 1993.
13. Gianolini S. Hagendorn, Switzerland: Medical Software Solutions GmbH. Available from: http://www.vodca.ch
14. Wang L, Yorke E, Desobry G, Chuien-Shou CS. Dosimetric advantage of using 6MV over 15MV photons in conformal therapy of lung cancer: Monte Carlo studies in patient geometries. J Appl Clin Med Phys 2002; 3: 51-9.
15. FitzGerald TJ, Urie M, Ulin K, Laurie F, Yorty J, Hanusik R, et al. Processes for quality improvements in radiation oncology clinical trials. Int J Radiat Oncol Biol Phys 2008; 71: S76-9. doi: 10.1016/j.ijrobp.2007.07.2387
16. Ibbott GS, Followill DS, Molineu A, Lowenstein JR, Alvarez PE, Roll JE. Challenges in credentialing institutions and participants in advanced technology multi-institutional clinical trials. Int J Radiat Oncol Biol Phys 2008; 71: S71-5. doi: 10.1016/j.ijrobp.2007.08.083
17. Purdy JA. Quality assurance issues in conducting multi-institutional advanced technology clinical trials. Int J Radiat Oncol Biol Phys 2008; 71: S66-70. doi: 10.1016/j. ijrobp.2007.07.2393
18. Purdy JA, Poortmans P, Aird E, Purdy JA, eds. Quality and safety in radiotherapy. New York, NY: Taylor & Francis; 2011. pp. 197-207.
19. Peters LJ, O'Sullivan B, Giralt J. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol 2010; 28: 2996-3001. doi: 10.1200/JCO.2009.27.4498
20. Ohri N, Shen X, Dicker AP, Doyle LA, Harrison AS, Showalter TN. Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials. J Natl Cancer Inst 2013; 105: 387-93. doi: 10.1093/jnci/djt001
21. Ibbott GS, Hanson WF, O'Meara E. Dose specification and quality assurance of Radiation Therapy Oncology Group protocol 95-17; a cooperative group study of iridium 192 breast implants as sole therapy. Int J Radiat Oncol Biol Phys 2007; 69: 1572-8. doi: 10.1016/j.ijrobp.2007.08.011
22. Bekelman JE, Deve JA, Vikram B, Bentzen SM, Bruner D, Curran WJ Jr, et al. Redesigning radiotherapy quality assurance opportunities to develop an efficient, evidence based system to support clinical trials - report of the National Cancer Institute work group on radiotherapy trials quality assurance. Int J Radiat Oncol Biol Phys 2012; 83: 782-90.
23. Weber DC, Poortmans PM, Hurkmans CW, Aird E, Gulyban A, Fairchild A. Quality assurance for prospective EORTC radiation oncology trials: the challenges of advanced technology in a multicentre international setting. Radiother Oncol 2011; 100: 150-6. doi: 10.1016/j. radonc.2011.05.073